Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous; 0.5 mL in single-dose vial) |
| Drug Class | Vaccines |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F)
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Welders exhibited a statistically significant increase in the likelihood of developing invasive pneumococcal disease (IPD) compared to non-welders, with an odds ratio of 2.59 (95% confidence interval (CI) 2.00-3.35).
- The standardized mortality ratio (SMR) for welders dying from IPD was 2.42 (95% CI 1.96-2.99).
- Among 72 IPD cases, serotype 4 was most prevalent (60.3%), followed by serotype 12F (19.2%) and serotype 8 (8.2%), which may influence vaccine effectiveness based on targeted serotype coverage.
- Welders and workers exposed to welding fumes and metal dusts show a significantly increased risk of developing and dying from IPD, with an odds ratio of 2.59 (95% CI 2.00-3.35) for developing IPD and a SMR of 2.42 (95% CI 1.96-2.99) for mortality, suggesting the importance of targeted vaccination. Serotype distribution (serotype 4 at 60.3%, serotype 12F at 19.2%, and serotype 8 at 8.2%) may inform vaccination strategies for these occupational groups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pneumovax 23 (pneumococcal vaccine polyvalent) Prescribing Information. | 2023 | Merck & Co., Inc., Rahway, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Vaccinating Welders against Pneumococcus: Evidence from a Systematic Review and Meta-Analysis | 2023 | Vaccines |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)—part 2: inactivated vaccines | 2021 | Journal of the Canadian Association of Gastroenterology |
| Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices | 2019 | US Department of Health and Human Services/Centers for Disease Control and Prevention |
| 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases | 2019 | Annals of Rheumatic Disease |